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Seven oliguric patients with severe ovarian hyperstimulation
syndrome following gonadotrophin treatment for in-vitro
fertilization or gamete intra-Fallopian transfer, were treated
with low doses of dopamine by peripheral infusion. Five
patients were pregnant. The rationale for this therapeutic
approach was to increase renal blood flow and glomerular
filtration. In addition to dopamine, fluid intake was restricted
to 500 ml/day and a protein and salt-rich diet was provided
in order to increase serum osmolarity. Within 24—48 h from
the beginning of the dopamine treatment, the syndrome
started to regress in all cases. No adverse maternal or fetal
effects occurred. We conclude that dopamine therapy may
constitute a major advance towards the management of severe
ovarian hyperstimulation syndrome.
Key words: dopamine/ovarian hyperstimulation syndrome
Introduction
Ovarian hyperstimulation syndrome (OHS) is a well recognized
iatrogenic complication of gonadotrophin therapy during treat-
ment for infertility. Increased hormonal monitoring and ovarian
ultrasound examination have reduced the incidence and the
severity of OHS during ovarian stimulation for the induction of
ovulation for amenorrhoea. However, OHS cannot be completely
avoided because of the narrow margin which exists between the
successful induction of ovulation and the sudden growth of
multiple follicles leading to OHS. In addition, there has been a
rapid increase in the number of women treated by in-vitro
fertilization (TVF) and associated techniques, such as gamete intra-
Fallopian transfer (GIFT), with gonadotrophins which stimulate
the production of multiple follicles and oocytes, thus increasing
the likelihood of OHS in these patients. In our own infertility
programme, which has involved 1117 IVF and GIFT treatment
cycles, seven patients (0.6%) have experienced severe OHS.
A variety of treatments for OHS have been proposed but
because little is known about the physiology of the syndrome,
there is no general agreement on the management of these
patients. In the present paper, we report the results of a new
therapeutic approach based on the peripheral infusion of low doses
of dopamine. In OHS patients, there is a rapid and massive fluid
shift from the intravascular compartment into the peritoneal and
pleura! cavities due to increased capillary permeability (Haning
et al., 1985; Navot et al., 1987). The resulting hypovolaemia
leads to decreased renal perfusion and secondarily to increased
salt and water reabsorption in the proximal renal tubules. The
reabsorbed fluid and sodium are transferred rapidly to the 'third
space' and the patient remains hypovolaemic while ascites further
increases. A prolonged hypovolaemia can cause vasoconstric-
tion of afferent arterioles producing kidney failure as effective
perfusion of kidney parenchyma decreases.
Dopamine produces its renal effect by increasing renal blood
flow and glomerular filtration. This is accomplished via stimula-
tion of the dopaminergic receptors present in the vascular kidney
bed (Felder et al., 1984). The rationale for treating oliguric OHS
patients with dopamine is to avoid fluid and salt retention and
to prevent acute renal failure.
Materials and methods
Seven patients with severe OHS were admitted to hospital after
induction of multiple follicular growth using follicle stimulating
hormone (FSH, Metrodin; Serono Laboratories, Rome, Italy)
and human menopausal gonadotrophin (HMG, Pergonal; Serono
Laboratories, Rome, Italy), for IVF or GIFT as described
elsewhere (Gianaroli et al., 1986). In two cases, the
gonadotrophin-releasing hormone (GnRH) analogue buserelin
(Suprefact; Hoechst UK Ltd) was administered subcutaneously
3 weeks before and during ovarian stimulation. All patients were
given an ovulatory dose of 5000 or 10 000 IU human chorionic
gonadotrophin (HCG, Profasi; Serono Laboratories) 34 h prior
to oocyte recovery, and all received progesterone supplementa-
tion throughout the luteal phase (50 mg i.m./day) (Gestone;
AMSA Lab., Florence, Italy).
Abdominal discomfort which required hospitalization arose 7
and 6 days after HCG in the two non-pregnant women. The other
five patients, all pregnant, were admitted 15 to 18 days after
HCG. At the time of hospitalization all patients had greatly
enlarged ovaries, easily discernible by abdominal palpation, and
marked ascites. In five patients there was associated pleural effu-
sion. The clinical manifestation of this involved oliguria, signs
of hypovolaemia, weight gain and respiratory distress. Laboratory
tests showed an imbalance of electrolytes (low urinary excre-
tion), loss of serum total protein and slightly increased fibrinogen
in all cases.
In five cases, serum osmolarity was low. In five cases the
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Table I. Clinical and laboratory parameters at the time of hospitalization of patients suffenng from severe ovarian hyperstimulation syndrome
Patient number Normal range
Ascites
Hydrochorax
Diuresis (ml/24 h)
Blood pressure (mmHg
Pulse frequency/min
Ovarian volume (ml) Right/Left
Haematocnt (%)
Fibrinogen (mg %)
Serum total protein (g %)
Serum creatinine (mg %)
Serum Na (mEq/1)
Serum K (mEq/1)
Serum osmolality (mOsm/kg)
Unnary Na (mEq/24 h)
Urinary K (mEq/24 h)
Pregnancies (no. fetuses)
—
-
(1000-1500)
(120/80)
(60-80)
(100-200)
(37-42)
(150-400)
(6-8)
(0.5-1.2)
(132-145)
(4-4 5)
(278-305)
(130-220)
(50-100)
Yes
Yes
130
100/70
90
374/175
43
620
5.5
1.23
138
4.6
290
93
70
Yes (1)
Yes
Yes
250
100/65
96
314/332
35
536
5.6
1.2
138
4.2
269
45
23
Yes (3)
Yes
Yes
500
85/40
96
792/770
43
454
5.5
0 98
135
3.9
279
85
58
No
Yes
No
300
100/60
100
762/616
47
559
5.6
1.35
139
4.2
277
37
29
No
Yes
Yes
400
90/55
96
636/512
45
418
5.4
1.3
135
4.1
267
69
44
Yes(l)
Yes
No
280
100/70
110
361/332
48
500
5.6
1.21
140
4.9
279
53
40
Yes (3)
Yes
Yes
300
110/60
80
251/380
34
530
5.8
0.81
139
4.2
290
19
18
Yes (2)
haematocrit value increased >6—10%, indicating haemoconcen-
tration. In five cases, serum creatinine was above or at the upper
limit of the normal range, indicating inadequate renal function
due to decreased perfusion. Blood urea was in the normal range.
Management of the patients consisted of bed rest, restriction
of fluid intake to 500 ml/day, daily monitoring of urine output,
weight, abdominal girth and haematological, biochemical and
clotting parameters, as well as serial measurements of blood
pressure and pulse rate. In the pregnant women, a /3-subunit for
HCG assay was performed every 2 days. The patients were given
a protein- and salt-rich diet in order to increase oncotic and
osmotic blood pressure. An ultrasound pelvic scan was carried
out every 3—5 days.
Dopamine treatment commenced within 10 h of admittance to
hospital using an intravenous infusion pump (Terufusion,
STC/502; Terumo Corp., Tokyo, Japan) which strictly controlled
the dosage of dopamine delivered. The dopamine dosage used
was 4.32 mg/kg body weight/24 h. This dose was capable of
dilating renal vessels and increasing renal blood flow without
affecting blood pressure and pulse rate (Kirshan et al., 1988).
Dopamine treatment was continued until there was a complete
resolution of ascites. Plasma expanders or albumin were only
administered if required. Anticoagulants to prevent thrombo-
embolic phenomena were given if clotting factors were altered.
Results
The clinical details and urinary and blood parameters of patients
when admitted to hospital are shown in Table I.
In three cases, the first ultrasound examination revealed a
multiple implantation. One patient (no. 2) had twin gestational
sacs in the uterus and one in the left tube requiring salpingec-
tomy at laparotomy; nos. 6 and 7 had intrauterine triplets and
twins respectively.
In the two non-pregnant women, dopamine treatment was
required for only 7 days. In the pregnant women, dopamine
treatment was required for 9-22 days. The duration of treat-
ment was related to the magnitude of the increase of endogenous
HCG and was longest in those patients with triplets (18-22 days),
shortest in those women with a single fetus (9—10 days) and
\
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Fig. 1. Variation of diuresis ( ), weight ( ) and abdominal girth
( ) in the first 48 h of dopamine treatment in seven patients suffering
from severe ovarian hyperstimulation syndrome (Mean ± SD).
intermediate for those with twins (14 days). Despite restriction
of fluid intake to 500 ml/day, all patients showed a considerable
increase in diuresis and a concomitant decrease in weight and
abdominal girth within 24 to 48 h of dopamine treatment
(Figure 1). Urinary sodium and potassium excretion returned
rapidly to the normal range (Figure 2). When haemoconcentra-
tion was present at the time of hospitalization, the serial deter-
mination of haematocrit under treatment showed a rapid decrease
in all cases and it was stabilized between 35 and 40% by the
fourth day of treatment. Other altered biochemical parameters
required varying periods of time to return to normal: 3—7 days
for total plasma proteins and 4 - 8 days for serum creatinine.
These urinary and blood parameters then remained within the
normal range during the remainder of the treatment period.
Plasma expanders (500 ml) were infused into patient 2 on the
second and fourth days after laparotomy because of severe
hypotension. The classical treatment of infusing albumin to
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Table II. Variations of clinical
treatment
Patient number
Clinical signs
Weight (kg)
Abdominal girth (cm)
Diuresis (ml/24 h)
Pulse frequency/min
Ovarian volume (ml)
Right ovary
Left ovary
Laboratory data
Serum protein (g %)
Serum creatinine (mg %)
Fibnnogen (mg %)
Haematocnt (%)
and laboratory parameters between the onset and end of dopamine treatment in
1
- 3 9
- 7
+ 1270
- 1 8
-182
- 8 0
+ 1.4
-0.33
-330
- 3
2
-8 .4
- 5
+750
-12
-280
-320
+0.5
-0.1
-64
- 1
3
-8.1
-13
+700
-14
-141
-159
+ 1 2
- 0 3
- 7 5
- 6
4
-3.1
- 7
+ 700
-32
-370
-322
+ 1 4
-0.53
-264
-11
patients suffering from severe ovarian hyperstimulation
5
-f
-11
+ 1400
-16
-220
-150
+ 1.2
- 0 4
-127
- 6
6
-5 .5
12
+520
-22
+ 150
+ 140
+ 1 6
0
-63
15
7
-1 4
- 6
+400
0
-116
-134
+0 2
0
- 4 0
0
increase oncotic blood pressure was only needed in two of the
patients (nos. 1 and 2) in a very low dose (a total of 15 and 10 g
respectively). Despite high fibnnogen levels in all cases, we only
treated patients with heparin if alteration of other clotting
parameters was observed. It was known that elevation of plasma
fibnnogen is often associated with ascites without necessarily
indicating blood hypercoagulability.
During the monitoring period, two patients showed a mild
alteration in liver function tests [increased serum aspartate
aminotransferase (SGOT), serum alanine aminotransferase
(SGPT) and 7-glutamyl transpeptidase (7-GT)] as reported by
others (Younis et al., 1988; Ryley et al., 1990).
Dopamine infusion was stopped only when an ultrasonic
examination displayed a complete reabsorption of the peritoneal
fluid. At that time, all the parameters considered were within
the normal range. The ovaries were still enlarged in all subjects
at the completion of dopamine infusion. It was well known
(Schenker and Weinstein, 1978) that ovaries of OHS patients
require more time to return to their normal size than it takes for
the clinical syndrome to regress, particularly when endogenous
HCG stimulation of ovaries has occurred. No further complica-
tions were observed after discontinuation of dopamine in any of
the women.
In Table II, the progression of the values of the clinical and
laboratory tests between the start and finish of treatment are
shown.
To date, five pregnant patients have delivered seven healthy
babies. Patient nos. 6 and 2 spontaneously aborted one of the
intrauterine gestational sacs in the first trimester, carrying to term
normal twins and a singleton respectively.
Discussion
All treatments proposed in the literature for severe OHS are to
some extent controversial. Intravenous administration of volume
expanders to correct hypovolaemia (Schenker and Weinstein,
1978) can increase intravascular volume only transiently and can
cause a further increase of interstitial fluid accumulation. This
must only be used as an emergency measure in the correction
of frank hypotension or renal shut-down.
Diuretics alone are ineffective in evacuating fluid accumulated
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Fig. 2. Variation of urinary excretion of sodium and potassium salts
in the first 48 h of dopamine treatment in seven patients suffering from
severe ovarian hyperstimulation syndrome (mean ± SD).
in the 'third space' and as they primarily influence the distal
tubules, would have only minimal effects. Indomethacin, as a
blocker of prostaglandin biosynthesis, was successfully used for
reducing capillary permeability (Knox, 1974; Schenker and
Polischuk, 1976) but teratogenic effects are not completely
excluded.
Rigid fluid and salt restriction has been demonstrated to be
useful in minimizing further ascite formation (Shapiro et al.,
1977) but 10 days were necessary before regression of the
syndrome began. Moreover, sodium and fluid restriction as the
only treatment may induce hypovolaemic shock when the
intravascular compartment is already depleted.
In our study, the association of dopamine treatment to increase
renal perfusion, and imposition of dietary sodium and proteins
to increase serum osmolarity caused fluids to be drawn rapidly
from the 'third space' into the intravascular compartment and
to be removed through a rise in urine production. This is clearly
demonstrated by the negative fluid balance associated in all
Dopamine treatment for severe OHS
patients with a decrease in weight and abdominal girth. Moreover,
intravascular volume is maintained, despite severe fluid restric-
tion and the diuretic effect of dopamine, due to the reabsorption
of ascitic fluid.
It is well-known that OHS syndrome may spontaneously
regress, but when conception occurs it may also progressively
deteriorate in the first weeks of gestation because of endogenous
HCG stimulation (Schenker and Polishuk, 1975). The therapeutic
approach proposed in this study caused the syndrome to regress
rapidly and prevented further complications in all patients, even
when there was a high risk that the clinical situation might worsen
(multiple pregnancies).
Further studies are needed to confirm these results. In this
preliminary study, however, we found the therapeutic administra-
tion of low-dosage dopamine to be safe and effective in the
management of patients with severe ovarian hyperstimulation.
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